Digital health company Everly Health has introduced a comprehensive at-home collection kidney health test for chronic kidney disease (CKD).
The test is intended for health plans and employers to expand access to prevent, diagnose and treat CKD.
To assess kidney function through urine collection, the test combines an estimated glomerular filtration rate through blood collection, an estimation of kidney function and a urinary albumin-to-creatinine ratio.
When compared against standard collection methods, the methods utilised for this test have a correlation of more than 98.6%.
Furthermore, the test intends to reduce lifetime costs linked to CKD and diabetes by enhancing accessibility to testing and satisfying the 2024 KED HEDIS measure.
To ensure tests attain or exceed traditional laboratory tests’ accuracy, Everly Health leverages advanced technology and processes tests at Clinical Laboratory Improvement Amendments-certified and College of American Pathologists-accredited labs.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEverly Health Solutions chief commercial officer Dr Liz Kwo said: “Kidney disease affects 37 million adults in the United States but 90% are unaware they even have it, which makes it a silent killer.
“We have an opportunity to significantly change the course of chronic kidney disease in the United States by working to ensure early detection is available to people through the testing they need to protect their kidney health.”
Partnering with more than 100 enterprise clients, Everly Health is a virtual care provider that utilises advanced diagnostics and remote-based care to enhance the early detection and prevention of disease.
